Specialty vaccine company Valneva SE (Nasdaq: VALN), has sold an FDA Priority Review Voucher (PRV) for $103 million. The company will invest proceeds from the…
February 07, 2024
Telemedicine-based therapy provider, Talkspace (Nasdaq: TALK), has partnered with Bicycle Health to expand their respective patients’ access to virtual care. Bicycle Health is the nation’s…
February 05, 2024
Fractyl Health Stumbles on IPO
Metabolic therapeutics company, Fractyl Health (Nasdaq: GUTS), began its first day of trading on Thursday last week with a mixed response from the market. The…
February 05, 2024
Biotech Breakfast – Healthcare Equities Outperform; Alto Neuroscience and Fractyl Health IPO; Tyra Biosciences, ImmunityBio Surge
Healthcare equities outperformed last week with Managed Care a standout. The S&P 500 Healthcare Index gained +1.98% versus the S&P 500 Index which was up…
February 02, 2024
Atara Biotherapeutics’ Stock Soars on Phase 3 Epstein-Barr Virus Data for Lead Asset
Atara Biotherapeutics (NASDAQ: ATRA), a biotech company at the forefront of developing off-the-shelf cell therapies using the natural power of the immune system, experienced a…
February 02, 2024
Intelligent Bio Solutions Surges Over 150% on Revenue Results
Shares in medical technology company Intelligent Bio Solutions (Nasdaq: INBS) soared by more than 150% on Friday after the company reported its (unaudited) revenue results…
February 01, 2024
NeuroBo to Initiate Clinical Trial for New Obesity Treatment
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has received FDA clearance of its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist…
February 01, 2024
Vaccine Innovation Company, Vaxcyte, Prices $750M Public Offering; Completes Enrollment in Pneumococcal Trial
Vaccine innovation company, Vaxcyte (Nasdaq: PCVX) has announced pricing of a $750 million public offering which is expected to close on February 2, 2024. Last…
January 31, 2024
Vaxxinity Collaboration an Important Step Forward for Vaccine Development for Neurodegenerative Diseases
In encouraging news for those living with neurodegenerative diseases, Vaxxinity, Inc. (Nasdaq: VAXX) has entered into a research collaboration with the University of Florida’s (UF)…
January 31, 2024
Lexaria Submits IND for Hypertension Treatment
Global drug delivery innovator, Lexaria Bioscience (Nasdaq: LEXX) has taken an important step forward in its hypertension program after submitting an Investigational New Drug (IND)…
January 31, 2024
Kura Oncology Reports Positive Preliminary Data from “Most Exciting Investigational Agent” for Leukemia
Kura Oncology, Inc. (Nasdaq: KURA) has reported preliminary clinical data from the first 20 patients in a Phase 1 dose-escalation trial of the company’s potent…
Clinical stage pharmaceutical company, Essa Pharma (Nasdaq: EPIX), has presented updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide…